Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?
Top Cited Papers
Open Access
- 7 May 2011
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 38 (10), 1788-1797
- https://doi.org/10.1007/s00259-011-1833-x
Abstract
Purpose Peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin analogues is a treatment option for patients with disseminated neuroendocrine tumours (NET). A combination treatment using the high-energy 90Y beta emitter for larger lesions and the lower energy 177Lu for smaller lesions has been postulated in the literature.The aim of the study was to evaluate combined 90Y/177Lu-DOTATATE therapy in comparison to 90Y-DOTATATE alone. Methods Fifty patients with disseminated NET were included in the study prospectively and divided into two groups: group A (n = 25) was treated with 90Y-DOTATATE, whereas group B (n = 25) received the 1:1 90Y/177Lu-DOTATATE. The administered activity was based on 3.7 GBq/m2 body surface area in three to five cycles, with amino acid infusion for nephroprotection. Results The median overall survival time in group A was 26.2 months while in group B median survival was not reached. Overall survival was significantly higher in group B (p = 0.027). Median event-free survival time in group A was 21.4 months and in group B 29.4 months (p > 0.1). At the 12-month follow-up, comparison of group A vs group B showed stable disease (SD) in 13 vs 16 patients, disease regression (RD) in 5 vs 3 patients and disease progression (PD) in 3 vs 4 patients; 4 and 2 patients died, respectively. The 24-month follow-up results were SD in nine vs ten patients, RD in one patient vs none and PD in four patients in both groups; three and four patients died, respectively. Side effects were rare and mild. Conclusion The results indicate that therapy with tandem radioisotopes (90Y/177Lu-DOTATATE) provides longer overall survival than with a single radioisotope (90Y-DOTATATE) and the safety of both methods is comparable.This publication has 26 references indexed in Scilit:
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study GroupJournal of Clinical Oncology, 2009
- ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Chemotherapy in Patients with Neuroendocrine TumorsNeuroendocrinology, 2009
- 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years’ experienceEuropean Journal of Nuclear Medicine and Molecular Imaging, 2006
- Tyr3-Octreotide and Tyr3-Octreotate Radiolabeled with177Lu or90Y: Peptide Receptor Radionuclide Therapy ResultsIn VitroCancer Biotherapy & Radiopharmaceuticals, 2003
- Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginineEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- 90Y–DOTA–D‐Phe1–Try3– octreotide in therapy of neuroendocrine malignanciesPeptide Science, 2002
- Low-energy Electron Emitters for Targeted Radiotherapy of Small TumoursActa Oncologica, 2001
- Use of somatostatin analog in management of carcinoid syndromeDigestive Diseases and Sciences, 1989
- Partial residuals for the proportional hazards regression modelBiometrika, 1982
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958